Quince Therapeutics, Inc. (CRTX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Quince Therapeutics, Inc. (CRTX)
Company Performance

Current Price

as of Oct 18, 2024

$0.80

P/E Ratio

N/A

Market Cap

$34.4M

Description

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Metrics

Overview

  • HQSouth San Francisco, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerCRTX
  • Price$0.795+0.26%

Trading Information

  • Market Cap$34.40M
  • Float74.13%
  • Average Daily Volume (1m)43,562
  • Average Daily Volume (3m)157,597
  • EPS-$1.27

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$27.73M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$8.80M
  • EV-$12.74M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.73
Documents